Integrated Filing — IndAS



General information about company
Scrip Code 524372
NSE Symbol ORCHPHARMA
MSEI Symbol NOTLISTED
ISIN INE191A01027
Name of company ORCHID PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 26-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 26-May-2025   12:00:00
End date and time of board meeting 26-May-2025   15:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-11-11
Indicate Company website link for updated RPT policy of the Company www.orchidpharma.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2374787000 9219259000
Other income 62568000 319291000
Total income 2437355000 9538550000
2 Expenses
(a) Cost of materials consumed 1369446000 5854606000
(b) Purchases of stock-in-trade 12440000 26131000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1724000 -438511000
(d) Employee benefit expense 222424000 863606000
(e) Finance costs 39796000 145401000
(f) Depreciation, depletion and amortisation expense 87621000 344362000
(f) Other Expenses
1 Other Expenses 428865000 1678121000
Total other expenses 428865000 1678121000
Total expenses 2158868000 8473716000
3 Total profit before exceptional items and tax 278487000 1064834000
4 Exceptional items 0 0
5 Total profit before tax 278487000 1064834000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 0 0
9 Total tax expenses 0 0
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 278487000 1064834000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 278487000 1064834000
17 Other comprehensive income net of taxes 16675000 -7513000
18 Total Comprehensive Income for the period 295162000 1057321000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 507191000 507191000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.49 20.99
Diluted earnings (loss) per share from continuing operations 5.49 20.99
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.49 20.99
Diluted earnings (loss) per share from continuing and discontinued operations 5.49 20.99
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above results for the quarter and year ended March 31 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 26, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. n2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. n3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. nAs on March 31, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : n Statement of QIP Net Funds raised and utilisation nParticulars Amount as stated in Total amount utilised Balance amount as on Remarks n the Offer Document upto March 31, 2025 on March 31, 2025 kept n Rs. In Lakhst Rs. In Lakhs in Fixed Deposits in lakhs n1)Investment in OBPL, subsidiary, nfor setting up Jammu nManufacturing Facilityt 9000 4416t 4584t n2)Repayment/prepayment, in nfull or in part, of certain noutstanding borrowings navailed by the companyt 14100t 14100t -t n3)Funding capital expenditure n requirements for setting up a n new block at the API facility n of the Company in Alathur, nTamil Nadut 9982 36t 9946 n4)General corporate purposes 6098t 6372t 0t _ nTotalt 39180 24924t 14530 nAs per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on then proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on March 31, 2025. n Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. n4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. n5. The figures for the quarters ended 31st March, 2025 and 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. n6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the nCompany in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, nin compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, ngiving No objection to the said amalgamation. Further, the Honourable NCLT have pronounced the order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed off the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. The management of the respective Companies are taking steps to comply with the said Order. n n7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 6121209000
Capital work-in-progress 276914000
Investment property 0
Goodwill 0
Other intangible assets 11253000
Intangible assets under development 162236000
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 693461000
Trade receivables, non-current
Loans, non-current 1082432000
Other non-current financial assets 42698000
Total non-current financial assets 1818591000
Deferred tax assets (net) 513015000
Other non-current assets 198717000
Total non-current assets 9101935000
2 Current assets
Inventories 3263715000
Current financial asset
Current investments 0
Trade receivables, current 2418321000
Cash and cash equivalents 158708000
Bank balance other than cash and cash equivalents 1484119000
Loans, current 0
Other current financial assets 28287000
Total current financial assets 4089435000
Current tax assets (net) 26291000
Other current assets 484458000
Total current assets 7863899000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 16965834000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 507191000
Other equity 12733300000
Total equity attributable to owners of parent 13240491000
Non controlling interest
Total equity 13240491000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1316358000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total non-current financial liabilities 1316358000
Provisions, non-current 33872000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 367000
Total non-current liabilities 1350597000
Current liabilities
Current financial liabilities
Borrowings, current 426033000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 110234000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1594555000
Total Trade payable 1704789000
Other current financial liabilities
Total current financial liabilities 2130822000
Other current liabilities 3333000
Provisions, current 23660000
Current tax liabilities (Net) 216931000
Deferred government grants, Current
Total current liabilities 2374746000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 3725343000
Total equity and liabilites 16965834000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be recalssified to profit or loss 16675000 -7513000
Total Amount of items that will not be reclassified to profit and loss 16675000 -7513000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 16675000 -7513000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1064834000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 145401000
Adjustments for decrease (increase) in inventories -621454000
Adjustments for decrease (increase) in trade receivables, current -488992000
Adjustments for decrease (increase) in trade receivables, non-current 4976000
Adjustments for decrease (increase) in other current assets 90986000
Adjustments for decrease (increase) in other non-current assets 3198000
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 16939000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -82074000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 344362000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 68751000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -47626000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -565533000
Net cash flows from (used in) operations 499301000
Dividends received 0
Interest paid 215075000
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -9400000
Net cash flows from (used in) operating activities 274826000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 685417000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 1003535000
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 1085207000
Dividends received 0
Interest received 230256000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -373489000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 285558000
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -31134000
Net cash flows from (used in) financing activities 254424000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 155761000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 155761000
Cash and cash equivalents cash flow statement at beginning of period 2947000
Cash and cash equivalents cash flow statement at end of period 158708000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Singhi and Co. Yes 31-Aug-2025


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-Jun-2023
Amount Raised 4000000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Care Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review Remark 1nDelay in implementation of the object(s) w.r.t the object- Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu but the extent of delay is not ascertainable. nnCommentnAlathur project is for further processing of proposed 7ACA into intermediate goods or downstream products from Jammu Project. The Land acquisition for setting up 7ACA project at Jammu is delayed. Consequently, there is delay in setting up of API Facility at Alathur. Hence the major amount remained unutilised. Remark 2nDelay in implementation of the object(s) w.r.t the object- Investment in OBPL for setting up Jammu Manufacturing Facility but the extent of delay is not ascertainable.nnCommentnThe Land of around 203.8 Kanal (25.475 acres) at Jammu had been identified, out of which registration of 158.30 Kanal (19.79 acres) of land has completed and registration of the remaining land parcel is expect to be completed before August 2025. Bhoomi Pooja for the project was successfully performed on September 07, 2024. Construction of boundary and building work had been already started. Purchase orders for major equipments have also been placed.nnThe Land acquisition task has been given to Land aggregator who is getting the land from various farmers. Getting the agreement signed from various farmers has taken time. Further for this land Change of Land Use (CLU) or registration was required. This has led to delay in acquiring land.nn
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Investment in Orchid Bio Pharma Limited for setting up Manufacturing Facility in Jammu Not Applicable 900000000 0 441600000 0 Monitoring Agency in its Report dated May 15, 2024 had comments that The company has transferred Rs 49 crores from the Monitoring account to CC account. Of which the company apportioned Rs 22.96 crores as reimbursement for investment made in OBPL.
2 Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by our Company Not Applicable 1410000000 0 1410000000 0
3 Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu Not Applicable 998200000 0 3600000 0
4 General corporate purposes Not Applicable 609800000 0 637200000 0 * As per the QIP offer document the amount allocated for GCP was Rs.6098 Lakhs which was on the basis of proposed net proceeds after issue expenses, being Rs.39180 Lakhs. However, net Proceeds transferred to Monitoring Account was Rs.39454 Lakhs as against the proposed Net Proceeds of Rs.39180 Lakhs, therefore the GCP was revised to Rs.274 lakhs has been included in the GCP and therefore the GCP balance was revised to Rs.6372 Lakhs. Additioanlly Monitoring Agency vide its Report dated commented that The company has transferred Rs 49 crores from the Monitoring account to CC account. Of which the company apportioned Rs 26.04 crores towards the repayment of debit balance in the cc account under general corporate purpose.


Signatory Details
Name of signatory Kapil Dayya
Designation of person Company Secretary and Compliance Officer
Place Gurugram
Date 26-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Purchase of goods or services Approved 39900000 94863000 26436000
2 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Any other transaction lease rents recived Approved 9651000 2912000 1456000
3 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Sale of goods or services Approved 41177000 57770000 13154000
4 Orchid Pharma Limited DHANUKA AGRITECH LIMITED Related Party under sec2(76)(1v) Any other transaction lease rents paid Approved 3736000 415000 1373000
5 Orchid Pharma Limited DHANUKA AGRITECH LIMITED Related Party under sec2(76)(1v) Any other transaction Reimbursement of expenses Approved 77000 0 0
6 Orchid Pharma Limited ORBION PHARMACEUTICALS PRIVATE LIMITED Associate Company Sale of goods or services Approved 1020000 -63000 17000
7 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Subsidiary Company Loan Approved 756468000 293578000 1082432000 Loan 0.0012 Repayable on Demand subject to Agreement Unsecured For investing in capital project
8 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Subsidiary Company Interest received Approved 37049000 0 0
9 Orchid Pharma Limited OTSUKA CHEMICAL (INDIA) PVT LTD Related Party under Section 2(76)(iii) of the Companies Act,2013 Purchase of goods or services Approved 1259697000 359474000 578278000
10 Orchid Pharma Limited Synmedic Laboratories Related Party under Section 2(76)(iii) of the Companies Act,2013 Purchase of goods or services Approved 124000 47000 1000
11 Orchid Pharma Limited Synmedic Laboratories Related Party under Section 2(76)(iii) of the Companies Act,2013 Sale of goods or services Approved 2833000 1035000 2143000
12 Orchid Pharma Limited Synmedic Laboratories Related Party under Section 2(76)(iii) of the Companies Act,2013 Any other transaction lease rents recived Approved 7570000 0 0
13 Orchid Pharma Limited DHANUKA AGRITECH LIMITED Related Party under sec2(76)(1v) Any other transaction rental deposit paid Approved 0 1910000 1910000
14 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Subsidiary Company Any other transaction corporate gaurantee commission received Approved 52772000 0 0
Total value of transaction during the reporting period 2212074000